STAT3 and non-small cell lung carcinoma: showed the importance of PDE1A as a significant promoter of Non-small cell lung cancer (NSCLC) metastasis through regulating exosome release and activating the STAT3 pathway by interacting with YTHDF2, suggesting PDE1A as a potential therapeutic target for metastatic disease (28).